This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Takeda O-GlcNAcase (OGA) inhibitor, “compound 5i,” binds to the same site as prior sugar-based OGA inhibitors, but has surprisingly…
molecule
2 years ago ●
1 min read
The Eisai β-catenin/CBP inhibitor, E7386, is an orally active and selective inhibitor of the β-catenin/CBP protein-protein interaction, a key node…
molecule
2 years ago ●
1 min read
The Novartis BET bromodomain inhibitor, NVS-BET-1, is a new chemotype of BRD4 (BD1 and BD2) inhibitor. While we recently highlighted…
molecule
2 years ago ●
1 min read
The BMS HIV-1 maturation inhibitor, “compound 16,” is a potent derivative of the clinical candidate GSK3532795/955176, with double-digit nanomolar activity…
molecule
2 years ago ●
1 min read
The JNJ AR antagonist, JNJ-63576253, is a clinical molecule for prostate cancer that is active against both wild-type androgen receptor…
molecule
2 years ago ●
1 min read
The Henan EGFR inhibitor, dosimertinib, is a deuterated derivative of the approved covalent inhibitor, osimertinib. A metabolite of osimertinib, AZ5104,…
molecule
2 years ago ●
1 min read
Load More
